Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market
Bouncing back from late-phase fail, Minoryx pockets €51M to guide [...]
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battle
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight [...]
Addex’s eyelid data fail to make clear case for spasm expansion
Addex’s eyelid data fail to make clear case for spasm [...]
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway
Iovance sinks 50% as pivotal cell therapy data disappoint investors, [...]
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ for heavily pretreated patients
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ [...]
Chutes & Ladders—Alchemab CEO resigns immediately citing ‘personal reasons’
Chutes & Ladders—Alchemab CEO resigns immediately citing ‘personal reasons’ mbayer [...]
ASCO: Merck’s Keytruda combo data could spark hope for lymphoma patients who lack options
ASCO: Merck’s Keytruda combo data could spark hope for lymphoma [...]
Avadel’s shares crumble as narcolepsy drug delayed yet again, this time on patent issue
Avadel’s shares crumble as narcolepsy drug delayed yet again, this [...]
Vertex scoops up Catalyst’s complement pipeline for $60M cash
Vertex scoops up Catalyst’s complement pipeline for $60M cash mbayer [...]
With the right partner, Pfizer gains fast-track tag for previously shelved NASH drug
With the right partner, Pfizer gains fast-track tag for previously [...]